Bronchogen is a synthetic tetrapeptide bioregulator (sequence: Ala-Glu-Asp-Leu, AEDL) extensively investigated in laboratory settings for its interactions with bronchial epithelial cells, gene expression patterns, and processes related to lung tissue homeostasis. This ultrashort peptide, derived from motifs associated with bronchial structural elements, supports studies on epithelial integrity, inflammatory responses, and regenerative pathways in respiratory models.
Synthesized under GMP-aligned conditions, Bronchogen is supplied as lyophilized powder with rigorous quality verification, including structural confirmation via mass spectrometry, purity assessment by HPLC, and a complete third-party Certificate of Analysis (CoA) per batch to ensure reproducibility and reliability in research applications.
Key Scientific Features
- ≥98% purity confirmed by reverse-phase HPLC and electrospray mass spectrometry.
- Verified sequence: Ala-Glu-Asp-Leu (AEDL; molecular formula C₁₈H₃₀N₄O₉, MW 446.45 g/mol).
- Lyophilized format for enhanced stability and aseptic reconstitution in experimental protocols.
- Batch-specific third-party CoA documenting purity, identity, peptide content, and absence of impurities.
- Produced in GMP-aligned, ISO-compliant facilities.
- Optimized for investigations into tissue-specific bioregulation of bronchial mucosa, epithelial differentiation, and DNA interaction mechanisms.
Research-Referenced Attributes (Pre-clinical literature observations; no therapeutic claims)
- In rat models of chronic obstructive pulmonary disease induced by nitrogen dioxide exposure, Bronchogen administration associates with reduced neutrophilic inflammation, normalization of bronchoalveolar lavage fluid cellular composition, decreased pro-inflammatory cytokine and enzyme profiles, and restoration of bronchial epithelial structure and function (PMID: 30199201, https://pubmed.ncbi.nlm.nih.gov/30199201/).
- Organotypic culture and cell models indicate tissue-specific stimulation of differentiation markers (e.g., CXCL12, Hoxa3) in bronchial epithelial cells, with pronounced effects in aged cultures, supporting studies on age-related cellular processes (PMID: 22808515, https://pubmed.ncbi.nlm.nih.gov/22808515/).
- Biochemical investigations demonstrate Bronchogen’s interaction with DNA, increasing thermostability (melting temperature elevation by ~3.1°C in specific molar ratios) via binding to nitrogen bases without helix distortion, suggesting roles in chromatin modulation and gene regulation (PMID: 21240358, https://pubmed.ncbi.nlm.nih.gov/21240358/).
- Additional pre-clinical observations link short peptides like AEDL to normalization of epithelial composition, increased secretory immunoglobulin A and surfactant protein levels, and modulation of remodeling in obstructive lung models (various Khavinson-group studies, e.g., PMID: 26468022).
Why Researchers Choose Nationwide Peptides Bronchogen
- Aligns precisely with sequences referenced in Khavinson bioregulator studies on bronchial and pulmonary models.
- Provides maximum analytical transparency with full HPLC/MS verification and downloadable batch-specific CoA.
- Ensures batch-to-batch consistency for reproducible outcomes in longitudinal respiratory research.
- Preferred by laboratories examining inflammation, epithelial repair, aging, and gene regulation in lung systems.
- Offered in standard research vial sizes with competitive pricing and options for extended protocols.
For Research Use Only. This product is supplied strictly for in vitro and in vivo laboratory investigations by qualified researchers in controlled experimental settings. Statements regarding this product have not been evaluated by the FDA. It is not intended for human consumption, injection, diagnostic use, therapeutic application, or any non-research purpose.
